Brilinta, a new antiplatelet drug

August 2011

You'll hear lots of buzz about Brilinta, a new antiplatelet drug.

Brilinta (ticagrelor) will compete with Plavix (clopidogrel) and Effient (prasugrel)...for acute coronary syndrome or after a stent.

Plavix will still lead the pack...for a while. It was the first one approved and is used the most. But it's not perfect.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Antiplatelets Brilinta, a new antiplatelet drug
Hepatitis C two new protease inhibitors for hepatitis C, Incivek (telaprevir) and Victrelis (boceprevir)
Smoking Cessation new warnings about Chantix and an increased risk of cardiac events in patients with heart disease
Statins if statins increase the risk of diabetes
Psychiatry New VA guidelines for post-traumatic stress disorder
Anticoagulants new ORAL anticoagulant called Xarelto (zuh-REL-toe)
Respiratory & Allergy which long-acting bronchodilator to use first-line for COPD
Sunscreens New rules for sunscreens
Men's Health Staxyn (STAX-in), a new orally disintegrating tablet version of vardenafil (Levitra)
Men's Health Men are asking if they should continue taking finasteride (Proscar, etc) or dutasteride (Avodart, etc) to prevent prostate cancer
Vitamins & Minerals Is it ever necessary to give vitamin B12 by injection
Education and Training changes in how your CE units are reported